Bisphosphonates and glucocorticoid-induced osteoporosis: implications for patients with respiratory diseases

Cowan, Simone; Morin, Suzanne; Ernst, Pierre
May 1998
Thorax;May1998, Vol. 53 Issue 5, p331
Academic Journal
No abstract available.


Related Articles

  • Alendronic acid tops alfacalcidol for steroid-induced osteoporosis.  // Reactions Weekly;8/26/2006, Issue 1116, p3 

    The article reports on a study which found that treatment with alendronic acid is more effective than alfacalcidol for glucocorticoid-induced osteoporosis in patients with rheumatic diseases.

  • Bilateral Atypical Femoral Fracture in a Man on Long-Term Bisphosphonate and Glucocorticoid Therapy. Román, Manuel; de Prado, Antonio; de Tembleque, Federico Rodríguez // Case Connector;Apr-Jun2015, Vol. 5 Issue 2, p1 

    Case: We present here, to our knowledge, the first case of a male patient with a sequential bilateral atypical femoral fracture associated with long-term use of bisphosphonates to treat glucocorticoid-induced osteoporosis. Conclusions: Given the known effectiveness of bisphosphonates, both their...

  • Osteoporosis in men: an increasingly recognised health problem usually best treated with bisphosphonates. Adis International Limited // Drugs & Therapy Perspectives;Oct2005, Vol. 21 Issue 10, p7 

    Deals with the treatment of osteoporosis in men. Comparison of the incidence of osteoporosis in men with that in women; Causes of osteoporosis in men; Role of bisphosphonates in the treatment of the disease.

  • Long-term treatment of osteoporotic women with bisphosphonates does not impair the response to subsequently administered intravenous pamidronate. Yavropoulou, M.; Hamdy, N.; Papapoulos, S. // Osteoporosis International;Aug2013, Vol. 24 Issue 8, p2353 

    Summary: We addressed the question whether the response of osteoporotic patients to bisphosphonate treatment is reduced with time. Bisphosphonate-treated women with postmenopausal or glucocorticoid-induced osteoporosis showed adequate and consistent changes of bone markers to subsequently...

  • Management of Osteoporosis in Adults with Cystic Fibrosis. Hecker, Travis M.; Aris, Robert M. // Drugs;2004, Vol. 64 Issue 2, p133 

    Cystic fibrosis (CF) is the most common genetic disease that causes respiratory failure within the Caucasian population. The life span of patients with CF has gradually increased from a median of 2 years of age to >30 years. Concurrent with this increased lifespan, a variety of other...

  • Bisphosphonates and Osteonecrosis of Jaws. Vijay, Geetha; Raghavan, Vijay // Journal of Indian Academy of Oral Medicine & Radiology;Oct-Dec2012, Vol. 24 Issue 4, p330 

    Bisphosphonates are used to treat osteoporosis, Paget disease of bone and other metabolic bone diseases, multiple myeloma, and skeletal events associated with metastatic neoplasms. In 2003, the first reports describing osteonecrosis of the jaw (ONJ) in patients receiving bisphosphonates were...

  • Effects of Bisphosphonate Administration on the Bone Mass in Immune Thrombocytopenic Purpura Patients Under Treatment With Steroids. Nomura, Shosaku; Kurata, Yoshiyuki; Tomiyama, Yoshiaki; Takubo, Takayuki; Hasegawa, Minoru; Saigo, Katsuyasu; Nishikawa, Masakatsu; Higasa, Satoshi; Maeda, Yasuhiro; Hayashi, Kunio // Clinical & Applied Thrombosis/Hemostasis;12/01/2010, Vol. 16 Issue 6, p622 

    Immune thrombocytopenic purpura (ITP) is an acquired hemorrhage condition involving accelerated platelet consumption caused by antiplatelet autoantibodies. Although various therapeutic strategies are used to treat patients with ITP, the standard treatment method is steroid therapy. The most...

  • Fatal Esophageal Perforation With Alendronate. Famularo, Giuseppe; De Simone, Claudio // American Journal of Gastroenterology;Nov2001, Vol. 96 Issue 11, p3212 

    Presents a letter to the editor regarding the effect of alendronate on patients with glucocorticoid-induced osteoporosis.

  • Actonel and Fosamax Formulary Evaluation. Ball, Travis // Drug Utilization Review;Feb2002, Vol. 18 Issue 2, p1 

    Presents information on the drugs Actonel and Fosamax for the treatment of patients with osteoporosis and glucocorticoid-induced osteoporosis. Mechanism of action of the drugs; Administration considerations for biphosphonate; Indications and dosage.

  • Practice patterns in osteoporosis prevention in patients at risk for glucocorticoid-induced osteoporosis - a reply. Feldstein, A.; Nichols, G. A. // Osteoporosis International;Apr2006, Vol. 17 Issue 4, p636 

    A response by A. Feldstein and G. A. Nichols to a comment on their article "Practice patterns in osteoporosis prevention in patients at risk for glucocorticoid-induced osteoporosis" is presented.


Read the Article


Sign out of this library

Other Topics